Functional relevance of antiemetic control

This publication has 17 references indexed in Scilit:

• Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869
  Cancer, 2002
• Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis
  European Journal Of Cancer, 2001
• Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone
  Journal of Clinical Oncology, 2001
• Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
  Journal of Clinical Oncology, 1999
• Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
  New England Journal of Medicine, 1999
• Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
  British Journal of Cancer, 1997
• Effect of postchemotherapy nausea and vomiting on health-related quality of life
  Supportive Care in Cancer, 1997
• On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993
  Annals of Oncology, 1996
• Quality of life consequences of chemotherapy-induced emesis
  Quality of Life Research, 1992
• The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy.
  Journal of Clinical Oncology, 1988